Biotime Inc (BTX) 3.60 $BTX
BioTime, Inc.'s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development
Business Wire - Mon Sep 15, 8:01AM CDT
OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and Abcodia Ltd., a UK-based company focusing on the early detection of cancer, today announced their collaboration focused on the development of OncoCyte's blood-based PanC-Dx(TM) test for early detection of breast cancer. PanC-Dx(TM) is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. OncoCyte is currently sponsoring four clinical studies of PanC-Dx(TM) in bladder, breast, and lung cancer.
BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer
Business Wire - Thu Sep 11, 3:14PM CDT
BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity's development and commercialization arm, to conduct a clinical trial of Asterias' novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer.
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer
PR Newswire - Thu Sep 11, 5:00AM CDT
CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference
Business Wire - Tue Sep 09, 8:06AM CDT
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 16th Annual Healthcare Conference at 9:35 a.m. EDT on Wednesday, September 10, 2014. The conference will be held at the New York Palace Hotel in New York City. Dr. West will provide an update on product development by BioTime and its subsidiaries.
Commit To Buy BioTime At $2.50, Earn 27.5% Annualized Using Options
StockOptionsChannel.com - Fri Sep 05, 11:13AM CDT
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $2.97/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock
PR Newswire - Thu Sep 04, 3:01PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date"
for determining holders of its Series A common stock entitled to receive BioTime, Inc. common share purchase warrants in Asterias' previously announced warrant distribution.
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:35PM CDT
BioTime, Inc. (BTX) announced that the FDA has granted permission to its subsidiary, Asterias Biotherapeutics, Inc., for a phase I/IIa study on AST-OPC1.
BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem(R)-Based Hydrogel for Vocal Fold Scarring
Business Wire - Thu Aug 28, 8:00AM CDT
BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime's proprietary HyStem(R)-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. Thibeault and her colleagues have demonstrated that localized delivery of HyStem(R) into injured vocal folds resulted in a significant improvement in function. Under a sponsored research agreement, Dr. Thibeault's laboratory will evaluate HyStem(R)-based hydrogels to identify formulations with optimum properties for reducing scarring. Upon completion of these preclinical studies, an investigator-initiated clinical trial in patients with vocal fold scarring due to disease or prior surgical interventions is planned, under the direction of Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in Belgium, subject to institutional and regulatory approval.
BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury
Business Wire - Wed Aug 27, 8:01AM CDT
--FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million in Trial Funding
Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
PR Newswire - Wed Aug 27, 5:00AM CDT
Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the successful completion of the Phase 1 clinical study of the product, and is designed to assess safety and activity of escalating doses of AST-OPC1 in patients with complete cervical spinal cord injuries, the first targeted indication for AST-OPC1 and the first of future product registration clinical trials.
Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
PR Newswire - Mon Aug 25, 6:00AM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business strategy and product development pipeline.
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
PR Newswire - Thu Aug 21, 6:00AM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy" Arno and Natale ("Nat" Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three of whom are independent.
BioTime Receives FDA Premarket Notification Clearance for Premvia(TM) 510(k)
Business Wire - Tue Aug 12, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA's Center for Devices and Radiologic Health that Premvia(TM) has been cleared for marketing as a Class II medical device. Premvia(TM)is the first FDA-cleared member of BioTime's HyStem(R) family of hydrogels, which are designed to mimic the natural structures of the human body's extracellular matrix. According to the FDA clearance, the product is indicated for the management of wounds including: partial thickness, full-thickness, tunneling wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, donor skin graft sites, post-Moh's surgery, post-laser surgery, podiatric wounds, wound dehiscence, abrasions, lacerations, second degree burns, skin tears and draining wounds.
BioTime Announces Second Quarter 2014 Results and Recent Developments
Business Wire - Tue Aug 12, 7:01AM CDT
--IND amendment pending for expanded clinical trials of AST-OPC1
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial
Business Wire - Thu Jul 31, 8:01AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx(TM) bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.
Asterias Biotherapeutics Announces Live Investor Webcast
PR Newswire - Thu Jul 24, 2:30PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. In accordance with applicable rules and regulations of the Securities and Exchange Commission, the webcast may be viewed only concurrently with the live presentation.
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
Business Wire - Mon Jul 14, 8:01AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologies foundational to BioTime's businesses. The new patents add to the largest known patent estate under one corporate umbrella in the field of pluripotent stem cell technology known as "regenerative medicine" with over 600 existing patents and patent applications owned or licensed to BioTime and its subsidiaries worldwide.
BioTime announces USD13.0m from equity financing of common stock & warrants
M2 - Wed Jun 18, 6:01AM CDT
Biotechnology company BioTime (NYSE MKT:BTX) said on Tuesday that its Asterias Biotherapeutics' subsidiary has raised USD12.5m through the sale of common shares and the issuance of warrants to investors.
BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing
Business Wire - Tue Jun 17, 8:01AM CDT
--Substantially strengthens Asterias' cash position
BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO
Business Wire - Tue Jun 17, 7:30AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro Lichtinger, President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc. ("Asterias" purchased from Asterias 200,000 shares of Asterias Series B common stock at a price of $2.34 per share. The funds raised by this purchase will be used in part to finance Asterias' therapeutic product development programs, which are based on the potential of using human embryonic stem (hES) cells to create innovative new therapies for diseases and conditions for which effective treatments are not presently available.
BioTime, Inc.'s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development
Business Wire - Mon Sep 15, 8:01AM CDT
OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), and Abcodia Ltd., a UK-based company focusing on the early detection of cancer, today announced their collaboration focused on the development of OncoCyte's blood-based PanC-Dx(TM) test for early detection of breast cancer. PanC-Dx(TM) is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. OncoCyte is currently sponsoring four clinical studies of PanC-Dx(TM) in bladder, breast, and lung cancer.
BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer
Business Wire - Thu Sep 11, 3:14PM CDT
BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity's development and commercialization arm, to conduct a clinical trial of Asterias' novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer.
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer
PR Newswire - Thu Sep 11, 5:00AM CDT
CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.
BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference
Business Wire - Tue Sep 09, 8:06AM CDT
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 16th Annual Healthcare Conference at 9:35 a.m. EDT on Wednesday, September 10, 2014. The conference will be held at the New York Palace Hotel in New York City. Dr. West will provide an update on product development by BioTime and its subsidiaries.
Commit To Buy BioTime At $2.50, Earn 27.5% Annualized Using Options
StockOptionsChannel.com - Fri Sep 05, 11:13AM CDT
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $2.97/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock
PR Newswire - Thu Sep 04, 3:01PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date"
for determining holders of its Series A common stock entitled to receive BioTime, Inc. common share purchase warrants in Asterias' previously announced warrant distribution. BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:35PM CDT
BioTime, Inc. (BTX) announced that the FDA has granted permission to its subsidiary, Asterias Biotherapeutics, Inc., for a phase I/IIa study on AST-OPC1.
BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem(R)-Based Hydrogel for Vocal Fold Scarring
Business Wire - Thu Aug 28, 8:00AM CDT
BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime's proprietary HyStem(R)-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. Thibeault and her colleagues have demonstrated that localized delivery of HyStem(R) into injured vocal folds resulted in a significant improvement in function. Under a sponsored research agreement, Dr. Thibeault's laboratory will evaluate HyStem(R)-based hydrogels to identify formulations with optimum properties for reducing scarring. Upon completion of these preclinical studies, an investigator-initiated clinical trial in patients with vocal fold scarring due to disease or prior surgical interventions is planned, under the direction of Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in Belgium, subject to institutional and regulatory approval.
BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury
Business Wire - Wed Aug 27, 8:01AM CDT
--FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million in Trial Funding
Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
PR Newswire - Wed Aug 27, 5:00AM CDT
Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the successful completion of the Phase 1 clinical study of the product, and is designed to assess safety and activity of escalating doses of AST-OPC1 in patients with complete cervical spinal cord injuries, the first targeted indication for AST-OPC1 and the first of future product registration clinical trials.
Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
PR Newswire - Mon Aug 25, 6:00AM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business strategy and product development pipeline.
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
PR Newswire - Thu Aug 21, 6:00AM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy"
Arno and Natale ("Nat" Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three of whom are independent. BioTime Receives FDA Premarket Notification Clearance for Premvia(TM) 510(k)
Business Wire - Tue Aug 12, 8:02AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA's Center for Devices and Radiologic Health that Premvia(TM) has been cleared for marketing as a Class II medical device. Premvia(TM)is the first FDA-cleared member of BioTime's HyStem(R) family of hydrogels, which are designed to mimic the natural structures of the human body's extracellular matrix. According to the FDA clearance, the product is indicated for the management of wounds including: partial thickness, full-thickness, tunneling wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, donor skin graft sites, post-Moh's surgery, post-laser surgery, podiatric wounds, wound dehiscence, abrasions, lacerations, second degree burns, skin tears and draining wounds.
BioTime Announces Second Quarter 2014 Results and Recent Developments
Business Wire - Tue Aug 12, 7:01AM CDT
--IND amendment pending for expanded clinical trials of AST-OPC1
BioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial
Business Wire - Thu Jul 31, 8:01AM CDT
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx(TM) bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.
Asterias Biotherapeutics Announces Live Investor Webcast
PR Newswire - Thu Jul 24, 2:30PM CDT
Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. In accordance with applicable rules and regulations of the Securities and Exchange Commission, the webcast may be viewed only concurrently with the live presentation.
BioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy
Business Wire - Mon Jul 14, 8:01AM CDT
BioTime, Inc. (NYSE MKT:BTX) announced today the issuance of 14 new patents to BioTime and its subsidiary companies. The patents issued in Australia, Canada, China, Japan, and the United States, cover a wide range of core technologies foundational to BioTime's businesses. The new patents add to the largest known patent estate under one corporate umbrella in the field of pluripotent stem cell technology known as "regenerative medicine" with over 600 existing patents and patent applications owned or licensed to BioTime and its subsidiaries worldwide.
BioTime announces USD13.0m from equity financing of common stock & warrants
M2 - Wed Jun 18, 6:01AM CDT
Biotechnology company BioTime (NYSE MKT:BTX) said on Tuesday that its Asterias Biotherapeutics' subsidiary has raised USD12.5m through the sale of common shares and the issuance of warrants to investors.
BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing
Business Wire - Tue Jun 17, 8:01AM CDT
--Substantially strengthens Asterias' cash position
BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO
Business Wire - Tue Jun 17, 7:30AM CDT
BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Pedro Lichtinger, President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"
purchased from Asterias 200,000 shares of Asterias Series B common stock at a price of $2.34 per share. The funds raised by this purchase will be used in part to finance Asterias' therapeutic product development programs, which are based on the potential of using human embryonic stem (hES) cells to create innovative new therapies for diseases and conditions for which effective treatments are not presently available. 
